Fig. 1 · Structure

Documents & Downloads

Reversine

Cat. No. A13250 CAS 656820-32-5

human A3 adenosine receptor antagonist /Aurora inhibitor

Reversine is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 12 nM/13 nM/20 nM, respectively. Also used for stem cell dedifferentiation.

In Stock

Publications for Reversine

2 publications citing this product

  1. Amy H. Ide, .et al. , Mol Biol Cell, 2023, Jun 1;34(7):ar76 PMID: 37126397
  2. Hazheen K, .et al. , J Biol Chem, 2020, August 20 PMID: 32820050

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Reversine inhibited recombinant human MPS1 with IC50 values of 2.8 nM for full-length enzyme and 6 nM for the kinase domain at 50 µM ATP. AURORA B was also inhibited (IC50 98.5 nM), so the reported preference for MPS1 should not be interpreted as absolute target specificity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Aurora A 12 nM
Aurora B 13 nM
Aurora C 20 nM
human A3 adenosine receptor Ki 0.66 μM

In Vitro Studies

In nocodazole-arrested HeLa cells maintained with MG132, 10 µM reversine removed approximately 74% of kinetochore Mad2-GFP within 2 h, leaving a residual population. BubR1-GFP declined to almost undetectable levels within 10 min in parallel reporter cells. These results describe checkpoint-protein redistribution under the stated co-treatments. [2]

Recombinant kinase inhibition by reversine

Biochemical assay · Recombinant human full-length MPS1, MPS1 kinase domain and AURORA B–INCENP; comparison panel of mitotic kinases [1]

Reversine inhibited MPS1 more potently than AURORA B in the reported enzyme assays. The broader panel provides a bounded selectivity control, not evidence of universal target specificity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Full-length human MPS1 activity toward MAD1–MAD2IC50 2.8 nM[1]
MPS1 kinase-domain activity toward MAD1–MAD2IC50 6 nM[1]
Human AURORA B(1–344)–INCENP(835–903) activity toward histone H3IC50 98.5 nM[1]
Activity of BUB1, NEK2A, TAO1, PLK1, CDK1–CYCLIN B, HASPIN and PRP4Qualitative control result No significant inhibition reported at 1 µM reversine[1]

Literature-Reported Treatment Conditions

Treatment concentration
Reversine titrations for IC50 determination; 1 µM for the comparison panel
Exposure duration
1 h
Method
In-vitro phosphorylation at 30°C with 50 µM ATP; radiolabeled phosphate incorporation, SDS-PAGE and autoradiography
Vehicle
DMSO; methods specify DMSO or DMSO-dissolved drug in reaction mixtures
Reported limits
Exact replicate n is not stated in Figure 1 caption. Compound supplier/lot and salt specification were not established from the selected original material.
Methods and source locations

Compound reported in the paper: Reversine

Evidence concerns reported reversine material; no salt conversion, current A13250 lot equivalence, clinical efficacy or dosing recommendation is established.

Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases

Full-length human MPS1 activity toward MAD1–MAD2: Radiometric kinase assay; 50 µM ATP; 1 h at 30°C; densitometry and fitted log-dose response; graph error bars mean ± SEM. Replicate n not stated in the Figure 1 caption. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases

MPS1 kinase-domain activity toward MAD1–MAD2: Same Figure 1 radiometric assay framework; endpoint is enzyme inhibition, not a cell treatment dose. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases

Human AURORA B(1–344)–INCENP(835–903) activity toward histone H3: Radiometric kinase assay at 50 µM ATP; Figure 1A error bars mean ± SEM. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases

Activity of BUB1, NEK2A, TAO1, PLK1, CDK1–CYCLIN B, HASPIN and PRP4: Figure 1B control lanes versus reversine; BI2536 and roscovitine positive inhibition controls for PLK1 and CDK1. This is not a proteome-wide selectivity test. — Results: Reversine is a potent MPS1 inhibitor; Figure 1A–D and caption; Materials and methods: In vitro kinase assays and Purification of mitotic kinases

Live-cell kinetochore Mad2 and BubR1 eviction after reversine

Cell-based study · HeLa cells expressing Mad2-GFP or BubR1-GFP, arrested with 5 µM nocodazole for 16 h [2]

Under continued nocodazole and MG132, reversine reduced kinetochore Mad2-GFP substantially but left a residual population. BubR1-GFP declined to almost undetectable levels within 10 min. The markers were measured in parallel reporter cells, not simultaneously in the same cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Kinetochore-associated Mad2-GFP fluorescenceReported approximate reduction approximately 74% evicted within 2 h[2]
Kinetochore-associated BubR1-GFP fluorescenceQualitative time-course result Almost undetectable within 10 min[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM reversine
Exposure duration
2 h live-cell imaging after addition
Method
Spinning-disk confocal microscopy; three z planes every 5 min; matched acquisition without reversine used to correct photobleaching
Co-treatment
5 µM nocodazole maintained; 10 µM MG132 included to prevent anaphase onset
Reported limits
Reversine solvent/final vehicle concentration is not specified in the selected eviction assay methods. This experiment is not a reversine-alone viability or mitotic-exit assay.
Methods and source locations

Compound reported in the paper: Reversine; Compound label in the paper: Adooq Bioscience (reported supplier)

Evidence concerns reported reversine material; no salt conversion, current A13250 lot equivalence, clinical efficacy or dosing recommendation is established.

Results: The majority of kinetochore Mad2 is evicted by the phosphatase pathway; Figure 1A,E–I and caption; Methods: reversine eviction assays and Imaging and fluorescence quantification

Kinetochore-associated Mad2-GFP fluorescence: Background- and photobleaching-corrected live fluorescence, normalized to pretreatment; n = 23 cells from 2 replicates. Residual Mad2 remained; no complete-removal claim. — Results: The majority of kinetochore Mad2 is evicted by the phosphatase pathway; Figure 1A,E–I and caption; Methods: reversine eviction assays and Imaging and fluorescence quantification

Kinetochore-associated BubR1-GFP fluorescence: Live fluorescence; n = 17 cells from 2 replicates; one-phase fit reported t1/2 = 2.0 min, R² = 0.99. No exact percent inferred from graph. — Results: The majority of kinetochore Mad2 is evicted by the phosphatase pathway; Figure 1A,E–I and caption; Methods: reversine eviction assays and Imaging and fluorescence quantification

In Vivo Studies

In U14 tumor-bearing nude mice, reversine plus aspirin produced lower tumor weight than either drug alone (reported P < 0.05) and greater tumor-volume reduction. The result is a combination-treatment comparison; exact combination doses were not explicitly restated, and the experiment does not establish a survival benefit or MPS1-specific antitumor action. [3]

Reversine and aspirin comparison in U14 tumor-bearing mice

Animal study · Subcutaneous U14 cervical carcinoma tumors in female athymic BALB/c nude mice; 25 mice randomized among five reported treatment groups [3]

The combination group had lower tumor weight than either single-agent group (caption: P < 0.05), and lower tumor volume. Reversine monotherapy also showed lower tumor measurements than mock/DMSO controls visually, without an adopted exact effect size or single-agent significance claim. This experiment does not establish MPS1-dependent efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor weight in combination versus each single-agent groupReported comparison Combination lower; P < 0.05[3]
Tumor volume in the combination versus single-agent groupsQualitative result Combination reduced volume to a greater extent[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every 3 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Reversine alone
10 mg/kg
RPMI-1640 medium and DMSO groupsLower tumor weight/volume than mock and DMSO groups in Figure 4; no numerical effect or single-agent significance adopted.[3]
Aspirin alone (comparator)
1 µg/kg (as reported)
Medium/DMSO controls and combination groupTumor weight higher than combination group (Figure 4A caption, P < 0.05).[3]
Reversine plus aspirinReversine-alone and aspirin-alone groups; medium and DMSO groups also includedLower tumor weight than either single agent (P < 0.05); reduced tumor volume to a greater extent.[3]
Reversine alone
Model: Female athymic BALB/c nude mice, 6–8 weeks old, bearing subcutaneous U14 tumors
Reported limits: Treatment duration and final injection formulation not specified; n per plotted endpoint not specified.
Aspirin alone (comparator)
Model: Female athymic BALB/c nude mice, 6–8 weeks old, bearing subcutaneous U14 tumors
Reported limits: This is aspirin comparator dosing, not reversine dosing; no correction to a presumed intended unit made.
Reversine plus aspirin
Model: Female athymic BALB/c nude mice, 6–8 weeks old, bearing subcutaneous U14 tumors
Reported limits: Exact combination doses are not explicitly restated; do not assume single-agent doses were reused. Course and final injection formulation not specified.
Methods and source locations

Compound reported in the paper: Reversine; Compound label in the paper: Sigma-Aldrich (reported supplier)

Evidence concerns reported reversine material; no salt conversion, current A13250 lot equivalence, clinical efficacy or dosing recommendation is established.

Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Tumor weight in combination versus each single-agent group: Figure 4A and caption; measurements plotted at days 25 and 50. Caption does not identify exact group-specific n or define plotted error bars; no graph-derived numerical means adopted. — Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Tumor volume in the combination versus single-agent groups: Figure 4B and caption; volume estimated from two tumor diameters as L × S²/2. No numerical efficacy percentage inferred. — Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Reversine alone · Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Aspirin alone (comparator) · Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Reversine plus aspirin · Materials and methods: Reagents; Xenograft cervical carcinoma mouse model and in vivo anti-tumor analysis; Statistical analysis; Results: Effect of drug combination on tumor volume and weight in a mouse model; Figure 4A–B and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor, Antagonist
CAS Number 656820-32-5
Applications human A3 adenosine receptor antagonist /Aurora inhibitor
Formula C21H27N7O
Molecular Weight 393.5
SMILES
C1CCC(CC1)NC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)N5CCOCC5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (10.17 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Santaguida S, Tighe A, D'Alise AM, et al. Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine The Journal of cell biology (2010). PMID: 20624901 DOI: 10.1083/jcb.201001036 Source material
  2. [2] Ide AH, DeLuca KF, Wiggan O, et al. The role of kinetochore dynein in checkpoint silencing is restricted to disassembly of the corona Molecular biology of the cell (2023). PMID: 37126397 DOI: 10.1091/mbc.e23-04-0130 Source material
  3. [3] Qin HX, Yang J, Cui HK, et al. Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo Cytotechnology (2013). PMID: 23475158 DOI: 10.1007/s10616-012-9520-8 Source material

Publications

2 publications citing this product

  1. Amy H. Ide, .et al. , Mol Biol Cell, 2023, Jun 1;34(7):ar76 PMID: 37126397
  2. Hazheen K, .et al. , J Biol Chem, 2020, August 20 PMID: 32820050

Added to your cart

View Cart Checkout
Loading...